In a new report titled “Global Market Study on Hemoglobinopathy: Europe Estimated to be the Dominant Regional Market in 2016”, Persistence Market Research analyzes the performance of the global hemoglobinopathy market over an eight-year period and provides insights on the key factors and trends likely to influence the market during the forecast period (2016 – 2024). In terms of revenue, the global hemoglobinopathy market is projected to register a healthy CAGR of 8.3% over the forecast period owing to various factors, on which Persistence Market Research offers detailed insights.
The global hemoglobinopathy market is segmented based on indication type, test type, end users, and region. Based on an indication, the market is segmented into sickle cell disease, alpha thalassemia, and beta thalassemia. Beta thalassemia segment is expected to register a significant CAGR of 8.7% during the forecast period. Sickle cell disease segment is anticipated to grow at a CAGR of 8.3% over the forecast period.
View and Download Report Table of Contents (TOC), Figures, and Tables: http://www.persistencemarketresearch.com/market-research/hemoglobinopathy-market/toc
The market has been segmented based on major types of diagnostic tests such as red blood cell (RBC) count test, genetic testing, hemoglobin by high-performance liquid chromatography (HPLC) test, hemoglobin isoelectric (Hb IEF) focusing, hemoglobin electrophoresis (Hb ELP) test, and hemoglobin solubility test. The genetic testing segment is expected to expand at the highest CAGR of 9.2% over the forecast period due to increasing adoption of preventive measures such as genetic counseling and testing. The increasing popularity of prenatal and premarital genetic screening make these tests an attractive opportunity for market players.
Based on end users, the market has been segmented into hospitals, diagnostic laboratories, and clinics. The diagnostic laboratories segment is anticipated to account for the highest market share over the forecast period, registering a CAGR of 8.9% due to an availability of dedicated equipment, reagents, and trained technicians required to perform rather complex diagnostic procedures like genetic testing, Hb HPLC, and isoelectric focusing.
Request Samples of the Report for Analysis: http://www.persistencemarketresearch.com/samples/10007
The global hemoglobinopathy market has been segmented into five major regions: North America, Latin America, Europe, Asia-Pacific (APAC), and the Middle East & Africa (MEA). North America and Europe are expected to dominate the global hemoglobinopathy market with a maximum market share in 2016. North America and Europe collectively have been expected to account for more than 50% of the total global hemoglobinopathy market share in terms of value in 2016. Among emerging markets, Asia Pacific is estimated to exhibit the highest CAGR of 9.3% over the forecast period, due to an increase in the diagnosis rate.
For Buy Full Report for Single User @ http://www.persistencemarketresearch.com/checkout/10007
Company Name: Persistence Market Research
Contact Person: Rahul Singh
Address:305 Broadway, 7th Floor
City: New York
Country: United States